Boston Scientific Co. (NYSE:BSX) Shares Sold by Tandem Capital Management Corp ADV

Tandem Capital Management Corp ADV reduced its stake in shares of Boston Scientific Co. (NYSE:BSX) by 2.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,476 shares of the medical equipment provider’s stock after selling 1,400 shares during the quarter. Boston Scientific accounts for approximately 2.1% of Tandem Capital Management Corp ADV’s portfolio, making the stock its 12th largest holding. Tandem Capital Management Corp ADV’s holdings in Boston Scientific were worth $3,380,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Syon Capital LLC lifted its holdings in shares of Boston Scientific by 4.5% in the fourth quarter. Syon Capital LLC now owns 19,069 shares of the medical equipment provider’s stock valued at $1,102,000 after purchasing an additional 819 shares in the last quarter. Bailard Inc. purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $7,147,000. Tokio Marine Asset Management Co. Ltd. lifted its holdings in shares of Boston Scientific by 15.3% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 36,820 shares of the medical equipment provider’s stock valued at $2,129,000 after purchasing an additional 4,889 shares in the last quarter. GAMMA Investing LLC purchased a new stake in shares of Boston Scientific in the fourth quarter valued at about $472,000. Finally, PDS Planning Inc lifted its holdings in shares of Boston Scientific by 11.1% in the fourth quarter. PDS Planning Inc now owns 4,964 shares of the medical equipment provider’s stock valued at $287,000 after purchasing an additional 496 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In related news, EVP John Bradley Sorenson sold 16,351 shares of the firm’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the completion of the sale, the executive vice president now directly owns 50,638 shares of the company’s stock, valued at approximately $3,509,213.40. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Daniel J. Brennan sold 13,662 shares of the firm’s stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $65.86, for a total transaction of $899,779.32. Following the completion of the sale, the chief financial officer now directly owns 271,542 shares of the company’s stock, valued at approximately $17,883,756.12. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 16,351 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $69.30, for a total transaction of $1,133,124.30. Following the transaction, the executive vice president now owns 50,638 shares in the company, valued at $3,509,213.40. The disclosure for this sale can be found here. Insiders sold 50,979 shares of company stock valued at $3,418,529 over the last 90 days. Corporate insiders own 0.50% of the company’s stock.

Boston Scientific Trading Up 0.5 %

Shares of Boston Scientific stock traded up $0.39 during trading hours on Thursday, hitting $73.30. The company’s stock had a trading volume of 8,171,396 shares, compared to its average volume of 6,560,629. Boston Scientific Co. has a 1-year low of $48.35 and a 1-year high of $74.39. The business has a fifty day moving average of $67.68 and a 200 day moving average of $60.37. The company has a market capitalization of $107.54 billion, a PE ratio of 68.50, a P/E/G ratio of 2.42 and a beta of 0.78. The company has a quick ratio of 0.82, a current ratio of 1.32 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, January 31st. The medical equipment provider reported $0.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.51 by $0.04. Boston Scientific had a net margin of 11.19% and a return on equity of 15.99%. The company had revenue of $3.73 billion during the quarter, compared to analyst estimates of $3.59 billion. During the same quarter in the prior year, the business earned $0.45 earnings per share. As a group, equities analysts forecast that Boston Scientific Co. will post 2.25 EPS for the current year.

Analyst Upgrades and Downgrades

BSX has been the topic of several recent research reports. Oppenheimer upped their price target on shares of Boston Scientific from $58.00 to $68.00 and gave the company a “market perform” rating in a report on Thursday, February 1st. JPMorgan Chase & Co. upped their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of Boston Scientific from $72.00 to $82.00 and gave the company an “overweight” rating in a research note on Thursday. Royal Bank of Canada upped their price objective on shares of Boston Scientific from $78.00 to $82.00 and gave the company an “outperform” rating in a research note on Thursday. Finally, StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, March 16th. Three analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $74.27.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.